ClinicalTrials.gg
CompletedNCT06530212Updated Oct 19, 2026

Sleeve Gastrectomy With Jejuno-ileal Bypass Versus Single Anastomosis Sleeve Jejunal Bypass

An interventional study of SGJIB and SAS-JB in Obesity, Morbid, sponsored by Minia University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Minia University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Obesity, Morbid by Minia University — none open to participants now, none under way, none of them phase 3. Obesity, Morbid · Minia University.

Enrollment
5th of 18
200 · median 150
Started
2024
with 1 other
No phase
17 of 18
none open now
Registered
18th of 18
by date

Among the 18 studies in Obesity, Morbid by Minia University, this one is the 5th largest by enrollment, is one of 2 that started in 2024, is one of 17 with no phase, and was the 18th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

None of the 18 studies in Obesity, Morbid by Minia University is open now. The open studies under Obesity, Morbid, anywhere →

Where they have run

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Obesity, Morbid by Minia University as a file.
02

Study summary

sleeve gastrectomy with jejunoileal bypass (SGJIB) is a novel technique for the surgical treatment of obesity. The aim of the study is to compare this maneuver with single anastomosis sleeve jejunal bypass (SAS-JB)

Read the detailed description

200 patients will be randomly divided into to equal . Group 1 will be operated by sleeve gastrectomy with jejunoileal bypass with the anastomosis between the jejunum at about 100 cm from the duodeno-jejunal flexure and the ileum at 250 cm from the ileocaecal junction. and group 2 will be operated by single anastomosis sleeve jejunal bypass (SAS-JB) with biliary limb equal one third of total intestinal length.

03

Conditions studied

  • Obesity, Morbid

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obese patients with more than 40 with or without co-morbidity or more than 35 with co-morbidity
  • patients fit for laparoscopic surgery
  • give approval to share in the study

Exclusion criteria

Exclusion Criteria:

  • patients refused to share in the study
  • patients unfit for surgery
  • patients aged less than 18 and older than 60
  • patient with previous upper abdominal surgery either for obesity or other diseases
  • revisional bariatric procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    SGJIB

    Procedure: SGJIB

  • Active comparator
    SAS-JB

    Procedure: SAS-JB

Interventions

  • ProcedureSGJIB

    sleeve gastrectomy with jejunoileal bypass with anastomosis between the jejunum at about 100 cm from the duodeno-jejunal flexure and the ileum at 250 cm from the ileocaecal junction.

  • ProcedureSAS-JB

    single anastomosis sleeve jejunal bypass (SAS-JB) with biliary limb equal one third of total intestinal length.

06

What researchers measure

Primary outcomes

  1. Stoma complications

    any complication due to sleeve jejunal anastomosis

    Time frame: one year

Secondary outcomes

  1. weight loss at one year

    the effect of the 2 procedures on weight measured by percentage of excess weight loss

    Time frame: one year

  2. improvement of comorbidities

    change in comorbidities

    Time frame: one year

07

Study locations

1 site
  • Faculty of medicine
    Minya, 61511, Egypt
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Mar 2026, 17 months.

Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's 17 months is below that.

Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Oct 2025 → Mar 2026 and completion Nov 2025 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Jul 31, 2024
StartActual
Sep 28, 2024
Primary completionActual
Mar 20, 2026was Oct 2025
CompletionActual
Apr 20, 2026was Nov 2025
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 19, 2026
Primary completion
Oct 20, 2025→Mar 20, 2026 (actual)
Oct 19, 2026
Study completion
Nov 20, 2025→Apr 20, 2026 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Completed
    Primary completion Oct 20, 2025→Mar 20, 2026 (now actual)
    Study completion Nov 20, 2025→Apr 20, 2026 (now actual)
    + 6 other changes: verification date, oversight details, contact details, site details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06530212
Lead sponsor
Minia University
Responsible party
Alaa Mstafa Hassan Sewefy (professor of general and bariatric surgery, Minia University) — Principal investigator
First posted
Jul 31, 2024
Start date
Sep 28, 2024
Primary completion
Mar 20, 2026
Completion
Apr 20, 2026
Last update
Oct 19, 2026

Study contacts

Alaa Sewefy, professor
principal investigator · Minia University
Taha Kayed, MD
study director · Minia University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion